Consistent results have been shown that IL-6 is a pleiotropic regulator of prostate cancer cell growth, and serum IL-6 levels has prognostic significance in patients with metastatic prostate cancer [58,59]. This evidence concerns the gene IL6 and metastatic prostate carcinoma.